Continuous IOP monitoring

Article

Investigating tolerability of a diagnostic device in healthy and glaucomatous patients

"The role of IOP fluctuation as an independent predictive factor for glaucoma progression is still controversial,"6–10 she added. "Goldmann applanation tonometry (GAT) has been the most widely established indirect method for measuring IOP for many decades and is the gold standard."11–14

"We tested the first model for use in humans for the first time in healthy subjects and in glaucoma patients with the primary objective to investigate tolerability and side effects of the device during and after a 24-hour IOP monitoring period," explained Dr Lorenz. Taking both healthy subjects and glaucoma patients and excluding anyone who had worn contact lenses before, the team placed one sensor in each patient's test eye and performed examinations both before and after the 24 hour wearing period.

"To evaluate the level of discomfort of the device in the study eye at 24 hours, a visual analogue scale (VAS) was presented to the subject. VAS for each subject was scored between 0 and 100 mm, the number corresponding to the distance in millimetres of the subject's mark on the VAS line from the left end. Secondary endpoints included best corrected visual acuity (BCVA), pachymetry, epithelial defects, conjunctival erythema and corneal topography," she said. "Additionally, subjects were asked to fill in a diary which was collected at the end of the study."

A test was also performed initially to ensure that healthy and glaucoma patients could be analysed together, as the device had never been formally tested in healthy subjects before. Dr Lorenz explained that if the glaucoma patients had demonstrated severe discomfort in this trial there would have been some difficulty in proving that it was not significantly associated with ocular surface disease, therefore, healthy subjects were required to be used as controls. "However, contrary to our expectations, no significant differences between the two groups could be demonstrated and both groups were combined for analysis," she asserted.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.